Biocon’s net profit for the quarter ended June 30, rose 12.5 per cent to Rs 78.8 crore. Consolidated total income rose to Rs 576.7 crore from Rs 443.5 crore in the year-ago period, showing a growth of 30 per cent. The company’s board had approved the scheme of arrangement for merging the wholly owned subsidiary Biocon Biopharmaceuticals Ltd with it, subject to the approval of Karnataka HC.
Kiran Mazumdar-Shaw, CMD, stated, “We have seen strong performances across all our business verticals and this reflects the success of our segmented business model.”
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app